You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Zepbound
since
auto-detected in 35 stories
12 days ago
CVS will add Zepbound coverage on Oct. 1, and start covering Lilly's newly approved Foundayo pill on June 1.
40 days ago
Eli Lilly profits more than double as weight-loss drug sales soar ⊕
First-quarter sales of medication Zepbound increased 80 per cent to $4.2bn
Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket ⊕
Lilly hiked its full-year sales outlook by $2 billion, and also raised its adjusted profit guidance.
82 days ago
Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial ⊖
Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill, orforglipron.
88 days ago
Maker of Mounjaro writes scathing letter to warn of dangerous 'chemical reactions' in knock-off versions of weight-loss drug ○
The maker of blockbuster weight-loss drugs Mounjaro and Zepbound has issued an urgent warning against knockoff versions of the medications over 'critical safety issues.'
3 months ago
Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen ⊕
Eli Lilly hopes the device can be more convenient for Zepbound users and lead to more people taking the drug.
Lilly's Zepbound and Taltz improve psoriasis symptoms, drive weight loss in study ⊕
Eli Lilly said on Wednesday the combined use of its weight-loss drug Zepbound with psoriasis treatment Taltz showed better results in a late-stage study.
Weight-loss race: how switch from injections to pills is expanding big pharma’s hopes ⊕⊕
found
a story from The Guardian ⚠️ › International
Tablets could make treatment more mainstream, with sector predicted to be worth $200bn by end of the decade
“I just felt slow: I want to be able to do anything my kids want to do and not have weight b…
4 months ago
We're raising our price target on Eli Lilly as the GLP-1 leader delivers a huge beat ⊕⊕
Combined sales for the company's blockbuster GLP-1 drugs Zepbound and Mounjaro exceeded $1 billion, with each showing triple-digit growth.
Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar ⊕
Eli Lilly's fourth-quarter earnings come as it tries to maintain its advantage over Novo Nordisk in the GLP-1 market.